Rilparencel, a percutaneous minimally invasive injectable product prepared from patients’ own kidney cells, is being developed to treat those with stage 3b or 4 CKD and either type 1 or type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback